For help on how to get the results you want, see our search tips.
732 results
Medicine
Orphan designations Remove Orphan designations filter
Maximum residue limits Remove Maximum residue limits filter
Withdrawn applications Remove Withdrawn applications filter
Shortages Remove Shortages filter
Orphan designation status
Withdrawn Remove Withdrawn filter
-
List item
Orphan designation: 2-hydroxy-N,N,N-trimethylethan-1-aminium (Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoate for: Treatment of pancreatic cancer
Date of designation: 24/03/2020, Withdrawn, Last updated: 16/02/2023 -
List item
Orphan designation: Berzosertib for: Treatment of small cell lung cancer
Date of designation: 18/07/2022, Withdrawn, Last updated: 07/02/2023 -
List item
Orphan designation: idursulfase for: Treatment of mucopolysaccharidosis type II (Hunter's syndrome)
Date of designation: 06/01/2021, Withdrawn, Last updated: 27/01/2023 -
List item
Orphan designation: Loncastuximab tesirine for: Treatment of diffuse large B-cell lymphoma
Date of designation: 20/08/2021, Withdrawn, Last updated: 26/01/2023 -
List item
Orphan designation: zanubrutinib for: Treatment of marginal zone lymphoma
Date of designation: 20/05/2021, Withdrawn, Last updated: 05/01/2023 -
List item
Orphan designation: regorafenib for: Treatment of glioma
Date of designation: 28/06/2019, Withdrawn, Last updated: 20/12/2022 -
List item
Orphan designation: Allogeneic retinal pigment epithelial cells genetically modified with a non-viral vector to express human alpha-L-iduronidase for: Treatment of mucopolysaccharidosis type I
Date of designation: 15/10/2021, Withdrawn, Last updated: 20/12/2022 -
List item
Orphan designation: Concizumab for: Treatment of haemophilia B
Date of designation: 12/10/2017, Withdrawn, Last updated: 14/12/2022 -
List item
Orphan designation: Humanised monoclonal IgG4 antibody against tissue-factor-pathway inhibitor (concizumab) for: Treatment of haemophilia A
Date of designation: 10/10/2012, Withdrawn, Last updated: 14/12/2022 -
List item
Orphan designation: Parsaclisib for: Treatment of marginal zone lymphoma
Date of designation: 25/07/2019, Withdrawn, Last updated: 13/12/2022 -
List item
Orphan designation: Tremelimumab for: Treatment of hepatocellular carcinoma
Date of designation: 09/12/2020, Withdrawn, Last updated: 09/12/2022 -
List item
Orphan designation: Allogeneic retinal pigment epithelial cells genetically modified with a non-viral vector to express beta-domain deleted human factor VIII for: Treatment of haemophilia A
Date of designation: 09/12/2020, Withdrawn, Last updated: 05/12/2022 -
List item
Orphan designation: Autologous CD34+ haematopoietic stem cells transduced with lentiviral vector encoding the human betaA-T87Q-globin gene (betibeglogene autotemcel) for: Treatment of beta thalassaemia intermedia and major
Date of designation: 24/01/2013, Withdrawn, Last updated: 30/11/2022 -
List item
Orphan designation: 1-(2-hydroxyethyl)-8-{[5-(4-methylpiperazin-1-yl)-2-(trifluoromethoxy) phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide fumarate salt (onvansertib) for: Treatment of acute myeloid leukaemia
Date of designation: 24/08/2018, Withdrawn, Last updated: 22/11/2022 -
List item
Orphan designation: 5-{(1R,2R)-2-[(cyclopropylmethyl)amino]cyclopropyl}-N-(tetrahydro-2H-pyran-4-yl)thiophene-3-carboxamide monohydrochloride for: Treatment of Kabuki syndrome
Date of designation: 19/11/2018, Withdrawn, Last updated: 22/11/2022 -
List item
Orphan designation: 6-((3S,4S)-4-methyl-1-(pyrimidin-2-yl-methyl)pyrrolidin-3-yl)-3-tetrahydropyran-4-yl-7H-imidazo(1,5-a)pyrazin-8-one (Tovinontrine) for: Treatment of sickle cell disease
Date of designation: 21/08/2020, Withdrawn, Last updated: 08/11/2022 -
List item
Orphan designation: Infigratinib for: Treatment of cholangiocarcinoma
Date of designation: 21/08/2020, Withdrawn, Last updated: 08/11/2022 -
List item
Orphan designation: (2S)-2-[(4R)-2-oxo-4-propyltetrahydro-1H-pyrrol-1-yl] butanamide (Brivaracetam) for: Treatment of progressive myoclonic epilepsies
Date of designation: 26/08/2005, Withdrawn, Last updated: 08/11/2022 -
List item
Orphan designation: 1-(3-methylbutanoyl)-L-aspartyl-L-threonyl-L-histidyl-L-phenylalanyl-L-prolyl-(L-cystinyl-L-isoleucyl-[(N6-(S)-4-carboxy-4-palmitamidobutanoyl)-L-lysinyl]-L-phenylalanyl-L-glutamyl-L-prolyl-L-arginyl-L-serinyl-L-lysinyl-L-glycinyl-L-cystinyl)-L-lysinamide, disulfide, acetate salt for: Treatment of beta thalassaemia intermedia and major
Date of designation: 24/08/2018, Withdrawn, Last updated: 21/10/2022 -
List item
Orphan designation: Teclistamab for: Treatment of multiple myeloma
Date of designation: 19/07/2022, Withdrawn, Last updated: 13/10/2022 -
List item
Orphan designation: Adeno-associated viral vector serotype rh10 containing the human factor IX gene for the treatment of haemophilia B- for: Treatment of haemophilia B
Date of designation: 14/12/2015, Withdrawn, Last updated: 11/10/2022 -
List item
Orphan designation: Ofranergene obadenovec for: Treatment of ovarian cancer
Date of designation: 16/10/2017, Withdrawn, Last updated: 26/09/2022 -
List item
Orphan designation: Adenovirus-associated vector containing human Fas-c gene (ofranergene obadenovec) for: Treatment of glioma
Date of designation: 06/06/2012, Withdrawn, Last updated: 26/09/2022 -
List item
Orphan designation: allogenic cytomegalovirus-specific cytotoxic T lymphocytes (adimlecleucel) for: Treatment of cytomegalovirus infection in patients with impaired cell-mediated immunity
Date of designation: 18/11/2016, Withdrawn, Last updated: 16/09/2022 -
List item
Orphan designation: Allogeneic CD34+ cells expanded ex vivo with an aryl hydrocarbon receptor antagonist (spanlecortemlocel) for: Treatment of acute lymphoblastic leukaemia
Date of designation: 16/12/2014, Withdrawn, Last updated: 16/09/2022